Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections
- PMID: 1312263
- DOI: 10.1097/00007691-199202000-00006
Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections
Abstract
The pharmacokinetics of rufloxacin, after repeated doses, was evaluated in 12 elderly patients with lower respiratory tract infections. Patients were given a single loading dose of 400 mg on the first day of treatment and single daily maintenance doses of 200 mg for the next 6-9 days. Serum concentrations of the drug were determined by high-performance liquid chromatography (HPLC) at regular intervals during treatment and fitted to a one-compartment open model for repeated doses. The maximum serum concentration after the first dose was 6.46 +/- 1.06 (mean +/- SEM) micrograms/ml and was reached in 4.3 +/- 0.8 h after the first administration. The elimination half-life was 28.7 +/- 4.1 h. The area under the serum levels-time curve from 0 to 24 h was 103 +/- 14 micrograms/h/ml after the first dose. On the last day of observation it increased to 155 +/- 28 micrograms/h/ml, with a mean extent of accumulation of 2.3 +/- 0.3 times. The elimination half-life was comparable to those in other studies in healthy young subjects, while plasma levels were about 80% higher. These results suggest that in elderly patients elevated drug concentrations may be reached in the serum. Although no untoward reactions related either to the drug concentration in serum or the dose have been noted with rufloxacin, this patient population should nevertheless be monitored carefully for adverse effects.
Similar articles
-
Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.Chemotherapy. 1991;37(6):389-97. doi: 10.1159/000238885. Chemotherapy. 1991. PMID: 1662127 Clinical Trial.
-
Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections.Infection. 1992 Mar-Apr;20(2):89-93. doi: 10.1007/BF01711071. Infection. 1992. PMID: 1316313
-
Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.Antimicrob Agents Chemother. 1992 Jun;36(6):1296-301. doi: 10.1128/AAC.36.6.1296. Antimicrob Agents Chemother. 1992. PMID: 1329618 Free PMC article. Clinical Trial.
-
[Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].Jpn J Antibiot. 1994 Oct;47(10):1241-58. Jpn J Antibiot. 1994. PMID: 7807686 Review. Japanese. No abstract available.
-
Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review.J Antimicrob Chemother. 1996 May;37 Suppl A:27-39. doi: 10.1093/jac/37.suppl_a.27. J Antimicrob Chemother. 1996. PMID: 8737123 Review.
Cited by
-
Rate and extent of drug accumulation after multiple dosing revisited.Clin Pharmacokinet. 2010 Jul;49(7):421-38. doi: 10.2165/11531190-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20528003 Review.
-
Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.Antimicrob Agents Chemother. 1993 Oct;37(10):2212-6. doi: 10.1128/AAC.37.10.2212. Antimicrob Agents Chemother. 1993. PMID: 8257146 Free PMC article. Clinical Trial.
-
Pharmacokinetics of rufloxacin in patients with impaired renal function.Antimicrob Agents Chemother. 1993 Apr;37(4):637-41. doi: 10.1128/AAC.37.4.637. Antimicrob Agents Chemother. 1993. PMID: 8388194 Free PMC article.
-
Biliary excretion of rufloxacin in humans.Antimicrob Agents Chemother. 1993 Dec;37(12):2545-9. doi: 10.1128/AAC.37.12.2545. Antimicrob Agents Chemother. 1993. PMID: 8109915 Free PMC article.
-
Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.Eur J Clin Microbiol Infect Dis. 1993 May;12(5):372-7. doi: 10.1007/BF01964437. Eur J Clin Microbiol Infect Dis. 1993. PMID: 8394816
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources